You are here

Mega deals morph into mega problems for Wall Street

Tie-ups that consolidate industries, move tax dollars offshore have been met with antitrust, legal challenges

The US Treasury unveiled new rules this week that had provisions that targeted a specific feature of the Pfizer and Allergan agreement, prompting both parties to walk away from the deal.

New York

IF 2015 was a dream year for Wall Street's top dealmakers, 2016 is starting to take a nightmarish turn.

Some of the mega transactions that had champagne corks popping in boardrooms are running into antitrust problems and, in the case of pharmaceutical firm Pfizer's US$160

Market voices on:

Powered by GET.comGetCom